Decoding Chronic Charcot Arthropathy: Molecular Mechanisms, Predictive Biomarkers, and Emerging Therapies

Area of Science:

• Orthopedics
• Endocrinology
• Immunology

Background:

• Chronic Charcot arthropathy is a severe complication of diabetic neuropathy, affecting 0.08-1% of patients.
• Pathogenesis involves genetic predisposition, metabolic disturbances (AGEs, vitamin D deficiency), and inflammatory dysregulation (RANKL/OPG axis, IL-17).

Purpose of the Study:

• To elucidate the multifactorial pathogenesis of chronic Charcot arthropathy.
• To evaluate diagnostic modalities and current management strategies.
• To explore emerging molecular therapies and risk stratification for prevention.

Main Methods:

• Review of literature on pathogenesis, diagnostics, and therapeutics.
• Analysis of imaging findings (MRI) and histopathology (bone biopsy).
• Assessment of risk stratification models combining genetic, biomarker, and clinical factors.

Main Results:

• RANKL/RANK/OPG axis dysregulation drives osteoclastogenesis; impaired Wnt signaling and AGEs affect healing.
• MRI is effective in differentiating Charcot from osteomyelitis; biopsy is gold standard for uncertainty.
• Risk stratification models show high accuracy (AUC 0.89) in identifying high-risk individuals.

Conclusions:

• Chronic Charcot arthropathy results from complex interactions between genetic, metabolic, and inflammatory pathways.
• Integrated risk assessment enables targeted preventive strategies, including vitamin D supplementation and off-loading.
• Emerging therapies targeting RANKL, IL-17, and Wnt pathways offer potential for disease modification.